Avidity Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in three major upcoming investor conferences in March 2025:
- TD Cowen 45th Annual Health Care Conference - March 4, 2025, at 3:10 p.m. ET
- Leerink Partners Global Healthcare Conference - March 11, 2025, at 1:00 p.m. ET
- Barclays 27th Annual Global Healthcare Conference - March 12, 2025, at 11:30 a.m. ET
The company will participate in fireside chats at each event. Live webcasts and archived replays will be available through Avidity's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RNA declined 4.49%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
- TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 p.m. ET
- Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:00 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 11:30 a.m. ET
Live webcasts of each event, up-to-date event details and archived replays will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302382513.html
SOURCE Avidity Biosciences, Inc.
FAQ
When is Avidity Biosciences (RNA) presenting at the TD Cowen Healthcare Conference 2025?
Which investor conferences is Avidity Biosciences (RNA) attending in March 2025?
How can investors access Avidity Biosciences' (RNA) conference presentations?
What type of therapeutic technology does Avidity Biosciences (RNA) develop?
